Targeting regulatory T cells in tumor immunotherapy

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

(2014) Yannick Bulliard et al.   IMMUNOLOGY AND CELL BIOLOGY

Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity

(2013) A. Marabelle et al.   CLINICAL CANCER RESEARCH

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

(2013) Yannick Bulliard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

(2013) Charles G. Drake et al.   Nature Reviews Clinical Oncology

TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

(2013) Kaori Sakuishi et al.   OncoImmunology

Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

(2012) Joannes FM Jacobs et al.   LANCET ONCOLOGY

What are regulatory T cells (Treg) regulating in cancer and why?

(2012) Theresa L. Whiteside   SEMINARS IN CANCER BIOLOGY

Multiple Antitumor Mechanisms Downstream of Prophylactic Regulatory T-Cell Depletion

(2010) Michele W.L. Teng et al.   CANCER RESEARCH

Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth

(2010) M. W. L. Teng et al.   CANCER RESEARCH

Signaling Through OX40 Enhances Antitumor Immunity

(2010) Shawn M. Jensen et al.   SEMINARS IN ONCOLOGY